Svar Life Science adopts Olink’s novel proteomics solutions technology to strengthen its position as a Biomarker Discovery Service partner and is the first CRO in the south of Sweden to offer the Olink® Proximity Extension Assay (PEA) technology for sample testing. The integration of the Olink® Signature Q100 instrument with the Olink® Target 96, Target 48, and Olink® Flex offering will allow Svar CRO Services to support even more biomarker discovery projects than before.
“We are excited to work with a leading, well-respected life science company like Olink. They have a great reputation for bringing flexible, scalable proteomics to the market,” said Anne Thjømøe, CEO of Svar Life Science. “Their Proteomics Solutions will help us support clients and drive the development of better, more targeted therapies and deliver new solutions tailored to customer requirements.”
“We are pleased to work together with Svar Life Science as it will further enhance the accessibility of the Olink proteomics platform to the scientific community. This aligns very nicely with our mission of accelerating research, better understanding of disease, more efficient and safer drug development, and enablement of earlier and more accurate diagnoses,” said Henk Mouthaan, Vice President Sales and Marketing EMEA, Olink.
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.